High Rate of Deep Remission for Relapsed/Refractory CLL Using Triple Regimen.

Published Date: 29 Apr 2024

Over 90% of cases are undetectable, and ctDNA is promising for early recurrence detection.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Chemo-Free Triplet Yields 68% Response Rate in Richter Transformation

2.

High Rate of Deep Remission for Relapsed/Refractory CLL Using Triple Regimen.

3.

Imfinzi + Imjudo, EU approved for patients with advanced lung cancer and non-small cell lung cancer: AstraZeneca

4.

Cardiomyocytes are shielded from chemotherapy damage by mitochondrial proteins.

5.

FDA Approves Subcutaneous Isatuximab for MM Indications


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot